"Expanding Next-Generation Muscle Disease Therapeutic Development Based on Technology Transfer Achievements"

The Myokine Convergence Research Center (MRC) at Korea University College of Medicine announced on the 4th that it has signed a memorandum of understanding (MOU) with MFC for the joint development of a treatment for sarcopenia in astronauts.

From left: Kim Hyunsoo, head of the MRC Center at Korea University College of Medicine, and Hwang Sungkwan, CEO of MFC, pose for a commemorative photo after signing an MOU to jointly develop a treatment for astronaut muscle atrophy. Korea University College of Medicine

From left: Kim Hyunsoo, head of the MRC Center at Korea University College of Medicine, and Hwang Sungkwan, CEO of MFC, pose for a commemorative photo after signing an MOU to jointly develop a treatment for astronaut muscle atrophy. Korea University College of Medicine

View original image

This agreement is a follow-up collaboration based on the technology cooperation agreement on rare and intractable muscular atrophy diseases and the technology transfer contract for sarcopenia treatments that were signed in 2022. Based on the research and development data accumulated so far, the two sides plan to expand the research scope to space environments and promote the development of next-generation treatments for muscle diseases.


Under the agreement, the two institutions will jointly develop treatments for a wide range of muscle diseases, including research and development of therapeutics for sarcopenia in astronauts, sarcopenia-related cachexia, and Duchenne muscular dystrophy. They will also continue to cooperate across the entire process of pharmaceutical research and commercialization.


Kim Hyunsoo, director of the MRC, said, "We have begun research on therapeutics to maintain the muscle health of astronauts in deep space exploration environments," adding, "Through an integrated myokine research system that can be applied clinically, we will present practical treatment alternatives to patients with sarcopenia and various muscle diseases." MFC CEO Hwang Seonggwan said, "This collaboration will serve as a starting point for the development of next-generation drugs in preparation for the space age."



Meanwhile, the Myokine Convergence Research Center at Korea University College of Medicine opened in October 2023. Focusing on myokines secreted from muscles, the center is pursuing the development of control technologies that can be applied not only to muscle diseases but also to cancer, aging, and degenerative brain diseases.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing